Modified virus injected into tumors shows promise for liver cancer

NCT ID NCT00554372

Completed Disease control Sponsor: Jennerex Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients had their disease controlled at 8 weeks and checked for side effects at two different dose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JX-594 (Pexa-Vec), a modified virus injected directly into tumors
What this could lead to: If successful, this could point toward a new way to control liver cancer that cannot be removed by surgery.
What could go wrong: This is a small, early-phase trial with only 30 participants. The virus may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Locations

Billings Clinic Cancer Center

Billings, Montana, 59101, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
McMaster University Medical Centre

Hamilton, Ontario, L8N 1Y3, Canada
Moores UCSD Cancer Center

La Jolla, California, 92093, United States
Pusan National University Hospital

Busan, South Korea
Samsung Medical Center

Seoul, South Korea
Shin Chon Severance Hospital / Yonsei University Medical Center

Seoul, South Korea
The Ohio State University

Columbus, Ohio, 43210, United States
University of Pittsburgh Medical Center - Liver Cancer Center

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.